NEPHROPLUS NSI Week ended 07 Aug 2026

Weekly Investor Report

NEPHROCARE HEALTH SERV L · Healthcare · Medical Care Facilities

Open interactive chart View report data
Latest close 694.2 INR
2.8% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 16.3% above the Trend Line and sits at 76.6% of its 52-week range. The latest completed week returned 2.8%, after a 7.0% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.

Setup score 50 out of 100
Latest Close 694.2 INR 7 Aug 2026
1W Return 2.8% latest completed week
4W Return 7.0% short-term follow-through
12W Return 7.8% quarterly tape
Trend Breadth 14.7% 5 of 34 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • The trend backdrop is active with a 5-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 2 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 2.8% Latest completed week; four-week move 7.0%. Indicator stack 25/51 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 58.65% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 10 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 16.3% above the Trend Line and sits at 76.6% of its 52-week range. The latest completed week returned 2.8%, after a 7.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7412-week average 0.57

12-week confirmation

Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.74Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 7.0% over four weeks, 7.8% over 12 weeks, and - over one year. The current trend has remained active for 5 consecutive weeks.

Performance by holding period

1W2.8%
4W7.0%
12W7.8%
26W30.9%
52W-
Active trend streak5 weeks
Active weeks in one year5
Trend breadth14.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.27Latest activity-pressure read.
Pressure change-43.3%Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 77%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength24/100Blend of value, momentum, and quality. Underlying universe rank 77; rank 1 is best.
Value13/100Relative valuation strength. Underlying universe rank 88; rank 1 is best.
Quality89/100Profitability and accounting quality. Underlying universe rank 12; rank 1 is best.
Momentum41/100Medium-term price momentum. Underlying universe rank 60; rank 1 is best.
Growth81/100Revenue and earnings growth. Underlying universe rank 20; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework20/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
90.8x
Price divided by trailing earnings.
Price / sales
7.0x
Market value relative to trailing revenue.
EV / EBITDA
28.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
1.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
57.9%
Gross profit retained from each unit of revenue.
Operating margin
14.0%
Operating profit retained from revenue.
Free-cash-flow margin
11.4%
Free cash flow generated from revenue.
Return on invested capital
9.7%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
32.9%
Latest one-year revenue growth.
EPS growth
14.5%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
227.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
7/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-5.6%
Net share repurchases relative to market value.
Shareholder yield
-5.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 10 relevant articles.

0 positive · 10 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-9.8%Distance below the 52-week high.
13-week volatility7.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher13 of 2613 weeks finished lower.
Best week+18.2%Week of 15 May.
Worst week-10.3%Week of 26 Jun.
Latest week+2.8%Week of 7 Aug.

Shape of recent returns

Strong gains8
Modest gains5
Flat weeks0
Modest losses8
Sharp losses5
Recent vol7.6%13-week weekly-return volatility.
Base vol5.8%52-week weekly-return volatility.
Up/down split19/14Count of positive and negative weeks in the 52-week window.
Average skew5.2% / -3.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape46/100

Trend, activity pressure, participation, and risk combine to a 46/100 tape read.

 Indicator analysis39/100

Latest 12-week confirmation: trend 5/12, activity pressure 6/12, relative leadership 0/12.

Activity pressure 0.74; 2 reversal markers Next-Week ExpectancyPositive 58.65%

Next-week expectancy is positive with a 58.65% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors41/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 90; Small Cap Core rank 94 SVQF20/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 1257.0 of 1576 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 10 relevant articles.

Nephrocare Health Services approves ESOP 2026 and INR 70 Cr Saudi collateral Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 2026694.2 INR2.8%596.8 INR582.4 INR0.27-539.3KOn
31 Jul 2026675.5 INR0.4%590.2 INR579.0 INR0.31-694.8KOn
24 Jul 2026673.1 INR5.9%583.5 INR575.9 INR0.35-1.1MOn
17 Jul 2026635.7 INR-2.0%576.9 INR572.8 INR0.38-525.0KOn
10 Jul 2026649.0 INR-3.4%570.7 INR570.7 INR0.47-1.8MOn
3 Jul 2026672.0 INR2.1%-568.0 INR0.36-86.9KOff
26 Jun 2026658.0 INR-10.3%-564.3 INR--0Off
19 Jun 2026733.8 INR-1.9%-560.8 INR--281.9KOff
12 Jun 2026748.2 INR10.7%-554.2 INR--204.5KOff
5 Jun 2026675.8 INR12.9%-546.4 INR--244.1KOff
29 May 2026598.7 INR-1.4%-541.0 INR--496.0KOff
22 May 2026607.5 INR-5.7%-538.5 INR--2.1MOff
15 May 2026644.0 INR18.2%-535.4 INR--2.5MOff
8 May 2026545.0 INR3.0%-530.2 INR--552.0KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context